Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report
2010

Toxic Risk of Combined Radiation and Erlotinib for Lung Cancer

Sample size: 1 publication Evidence: low

Author Information

Author(s): Hsieh Chen-Hsi, Chang Hou-Tai, Lin Shih-Chiang, Chen Yu-Jen, Wang Li-Ying, Hsieh Yen-Ping, Chen Chien-An, Chong Ngot-Swan, Lin Shoei Long, Chen Chun-Yi, Shueng Pei-Wei

Primary Institution: Far Eastern Memorial Hospital, Taipei, Taiwan

Hypothesis

Is the combination of stereotactic body radiotherapy and erlotinib safe and effective for treating non-small-cell lung cancer?

Conclusion

The combination of SBRT, HT, and erlotinib showed effective anti-tumor results, but potential risks of adverse effects should be monitored closely.

Supporting Evidence

  • The tumor shrank significantly after treatment.
  • The patient developed dyspnea and radiation pneumonitis three months post-therapy.
  • Erlotinib was well tolerated as maintenance therapy.

Takeaway

Doctors combined a special type of radiation therapy with a medicine to treat a man's lung cancer, and it worked well, but it also caused some serious side effects.

Methodology

The patient received erlotinib and underwent image-guided SBRT via helical tomotherapy, delivering a total tumor dose of 54 Gy in 9 fractions.

Potential Biases

Potential bias due to the lack of a control group and reliance on a single patient's outcomes.

Limitations

The study is based on a single case report, limiting generalizability.

Participant Demographics

A 77-year-old man with stage III non-small-cell lung cancer.

Digital Object Identifier (DOI)

10.1186/1471-2407-10-696

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication